Which diphosphonate for routine bone scintigraphy (MDP, HDP or DPD)?

Fruhling, Janos; Verbist, A; Balikdjian, Daniel

doi:10.1097/00006231-198606000-00004

Cited by 18 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fruhling et al . () found similar metastatic to normal bone ratio for HDP, DPD and MDP. Detectability of metastatic lesions was slightly superior for two of three MDP kits compared to the other products.…”

Section: Discussionmentioning

confidence: 74%

See 1 more Smart Citation

Evaluation of changes in Bone Scan Index at different acquisition time‐points in bone scintigraphy

Kaboteh

Minarik

Reza

et al. 2018

Clin Physio Funct Imaging

View full text Add to dashboard Cite

Bone Scan Index (BSI) is a validated imaging biomarker to objectively assess tumour burden in bone in patients with prostate cancer, and can be used to monitor treatment response. It is not known if BSI is significantly altered when images are acquired at a time difference of 1 h. The aim of this study was to investigate if automatic calculation of BSI is affected when images are acquired 1 hour apart, after approximately 3 and 4 h. We prospectively studied patients with prostate cancer who were referred for bone scintigraphy according to clinical routine. The patients performed a whole-body bone scan at approximately 3 h after injection of radiolabelled bisphosphonate and a second 1 h after the first. BSI values for each bone scintigraphy were obtained using EXINI bone software. A total of 25 patients were included. Median BSI for the first acquisition was 0·05 (range 0-11·93) and for the second acquisition 0·21 (range 0-13·06). There was a statistically significant increase in BSI at the second image acquisition compared to the first (P<0·001). In seven of 25 patients (28%) and in seven of 13 patients with BSI > 0 (54%), a clinically significant increase (>0·3) was observed. The time between injection and scanning should be fixed when changes in BSI are important, for example when monitoring therapeutic efficacy.

show abstract

Section: Discussionmentioning

confidence: 74%

“…Some BSI studies do not describe how the bone scans were performed (Dennis et al ., ; Reza et al ., ; Petersen et al ., ), when images from multiple hospitals were used. Previous studies have compared bone scans performed with different tracers (Bergqvist et al ., ; Fruhling et al ., ). Bergqvist et al .…”

Section: Discussionmentioning

confidence: 97%

Evaluation of changes in Bone Scan Index at different acquisition time‐points in bone scintigraphy

Kaboteh

Minarik

Reza

et al. 2018

Clin Physio Funct Imaging

View full text Add to dashboard Cite

show abstract

“…In contrast, in our study, imaging was performed with another similar radiopharmaceutical 99m Tc-2,3-dicarboxypropane-1,1-diphosphonate. We did not expect this difference to have any significant effect due to comparable pharmacokinetics and accumulation patterns reported by studies conducted during the approval process of the corresponding pharmaceuticals [36][37][38].…”

Section: Discussionmentioning

confidence: 83%

Analysis of Bone Scans in Various Tumor Entities Using a Deep-Learning-Based Artificial Neural Network Algorithm—Evaluation of Diagnostic Performance

Wuestemann

Hupfeld

Kupitz

et al. 2020

Cancers

View full text Add to dashboard Cite

The bone scan index (BSI), initially introduced for metastatic prostate cancer, quantifies the osseous tumor load from planar bone scans. Following the basic idea of radiomics, this method incorporates specific deep-learning techniques (artificial neural network) in its development to provide automatic calculation, feature extraction, and diagnostic support. As its performance in tumor entities, not including prostate cancer, remains unclear, our aim was to obtain more data about this aspect. The results of BSI evaluation of bone scans from 951 consecutive patients with different tumors were retrospectively compared to clinical reports (bone metastases, yes/no). Statistical analysis included entity-specific receiver operating characteristics to determine optimized BSI cut-off values. In addition to prostate cancer (cut-off = 0.27%, sensitivity (SN) = 87%, specificity (SP) = 99%), the algorithm used provided comparable results for breast cancer (cut-off 0.18%, SN = 83%, SP = 87%) and colorectal cancer (cut-off = 0.10%, SN = 100%, SP = 90%). Worse performance was observed for lung cancer (cut-off = 0.06%, SN = 63%, SP = 70%) and renal cell carcinoma (cut-off = 0.30%, SN = 75%, SP = 84%). The algorithm did not perform satisfactorily in melanoma (SN = 60%). For most entities, a high negative predictive value (NPV ≥ 87.5%, melanoma 80%) was determined, whereas positive predictive value (PPV) was clinically not applicable. Automatically determined BSI showed good sensitivity and specificity in prostate cancer and various other entities. Particularly, the high NPV encourages applying BSI as a tool for computer-aided diagnostic in various tumor entities.

show abstract

“…MDP on the other hand is superior to the other bone-seeking radiopharmaceuticals in detecting metastatic bone lesions [22]. So, we designed this study to demonstrate the presence of a possible negative effect of cisplatin on the bone uptake of Tc-99m MDP.…”

Section: Discussionmentioning

confidence: 99%

Does cisplatin chemotherapy decrease the MDP uptake of normal bone? An experimental study

et al. 2008

View full text Add to dashboard Cite

show abstract

Which diphosphonate for routine bone scintigraphy (MDP, HDP or DPD)?

Cited by 18 publications

References 0 publications

Evaluation of changes in Bone Scan Index at different acquisition time‐points in bone scintigraphy

Evaluation of changes in Bone Scan Index at different acquisition time‐points in bone scintigraphy

Analysis of Bone Scans in Various Tumor Entities Using a Deep-Learning-Based Artificial Neural Network Algorithm—Evaluation of Diagnostic Performance

Does cisplatin chemotherapy decrease the MDP uptake of normal bone? An experimental study

Contact Info

Product

Resources

About